You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 130 No. 6, June 1994 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Studies
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (120)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Topical Retinoic Acid (Tretinoin) for Melasma in Black Patients

A Vehicle-Controlled Clinical Trial

Candance K. Kimbrough-Green, MD; Christopher E. M. Griffiths, MD, MRCP; Lawrence J. Finkel, MD; Ted A. Hamilton, MS; Stella M. Bulengo-Ransby, MD; Charles N. Ellis, MD; John J. Voorhees, MD

Arch Dermatol. 1994;130(6):727-733.


Abstract



Background and Design
Melasma is an acquired, masklike, facial hyperpigmentation. The pathogenesis and treatment of melasma in black (African-American) patients is poorly understood. We investigated the efficacy of topical 0.1% all-trans-retinoic acid (tretinoin) in the treatment of melasma in black patients. Twenty-eight of 30 black patients with melasma completed a 10-month, randomized, vehicle-controlled clinical trial in which they applied either 0.1% tretinoin or vehicle cream daily to the entire face. They were evaluated clinically (using our Melasma Area and Severity Index), colorimetrically, and histologically.

Results
After 40 weeks, there was a 32% improvement in the Melasma Area and Severity Index score in the tretinoin treatment group compared with a 10% improvement in the vehicle group. Colorimetric measurements showed lightening of melasma after 40 weeks of tretinoin treatment vs vehicle. Lightening of melasma, as determined clinically, correlated well with colorimetric measurements. Histologic examination of involved skin revealed a significant decrease in epidermal pigmentation in the tretinoin group compared with the vehicle group. Side effects were limited to a mild ''retinoid dermatitis'' occurring in 67% of tretinoin-treated patients. Among the patients in this study in comparison with comparably recruited white patients, melasma was reported to have begun at a later age and was more likely to be in a malar distribution.

Conclusions: This controlled study demonstrates that topical 0.1% tretinoin lightens melasma in black patients, with only mild side effects.

(Arch Dermatol. 1994;130:727-733)



Author Affiliations



From the Dermatopharmacology Unit, Department of Dermatology, University of Michigan Medical Center, Ann Arbor.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Outcome Measures in Facial Plastic Surgery: Patient-Reported and Clinical Efficacy Measures
Rhee and McMullin
Arch Facial Plast Surg 2008;10:194-207.
ABSTRACT | FULL TEXT  

Efficacy of Glycolic Acid Peels in the Treatment of Melasma
Hurley et al.
Arch Dermatol 2002;138:1578-1582.
ABSTRACT | FULL TEXT  

Melasma: Etiologic and Therapeutic Considerations
Grimes
Arch Dermatol 1995;131:1453-1457.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1994 American Medical Association. All Rights Reserved.